Masimo Corporation's Preliminary Financial Results for 2024
Masimo Corporation (NASDAQ: MASI) has recently unveiled its select preliminary financial results for the fourth quarter and full-year ending December 28, 2024, along with its initial guidance for the fiscal year 2025. The company’s commitment to enhancing patient outcomes and the cost of care continues to reflect in its financial performance.
Fourth Quarter 2024 Highlights
The consolidated revenue for the fourth quarter is projected to be around $601 million, marking a growth of 9%. In the healthcare segment, revenue is expected to reach approximately $368 million, reflecting an 8% increase. Interestingly, the non-healthcare revenue is anticipated to be about $232 million, demonstrating a robust growth of 11%.
Full-Year 2024 Financial Results
For the entire year 2024, Masimo anticipates consolidated revenue to be about $2,094 million. This represents a 2% growth against the previous year's results. Of this figure, healthcare revenue is expected to total approximately $1,395 million, indicating a commendable 9% growth. However, non-healthcare revenue estimates show a decline of about 10%, which reflects the ongoing adjustments in that segment.
GAAP and Non-GAAP Earnings
The company predicts that its non-GAAP earnings per diluted share will likely exceed $4.10, which represents the upper limit of previous estimates. These figures are vital for investors who follow the non-GAAP measures closely.
Guidance for 2025
Looking ahead, Masimo is setting expectations for healthcare revenue between $1,500 million to $1,530 million for the fiscal year 2025, which corresponds to a growth rate of 8% to 11% on a constant currency basis. Anticipated non-GAAP operating profit is estimated to be between $398 million and $406 million, along with projected non-GAAP earnings per diluted share expected to lie between $4.90 and $5.10.
Conference Call and Future Insights
Masimo plans to conduct an investor conference call to discuss its complete fourth-quarter and full-year results after the market closes on February 25, 2025. This dialogue will provide a comprehensive breakdown of the financial performances and future expectations.
The Role of Masimo Technologies
At Masimo, the commitment to innovative healthcare solutions continues to be a priority. The company's advancements in monitoring technologies are crucial for enhancing patient safety and outcomes. Its flagship product, Masimo SET® Measure-through Motion and Low Perfusion™, demonstrates consistent efficacy in delivering accurate results, significantly improving patient monitoring across various clinical settings.
Impact on Healthcare and Wellness
Masimo's solutions are integrated into numerous hospitals, contributing to a reduction in costs associated with patient care. Ongoing innovations aim to further transform how healthcare providers track and manage patient health.
About Masimo Corporation
Masimo Corporation, recognized on the NASDAQ under the ticker MASI, is a pioneering global technology company committed to developing and producing innovative monitoring solutions. Their range of products includes groundbreaking measurements and technologies tailored for a variety of clinical and non-clinic environments, showcasing their dedication to improving patient outcomes while minimizing care costs.
Frequently Asked Questions
What are Masimo's projected revenues for 2024?
The company estimates consolidated revenue for 2024 to be around $2,094 million.
What growth in healthcare revenue does Masimo expect for 2025?
Masimo projects healthcare revenue for 2025 to grow between $1,500 million and $1,530 million.
When will Masimo hold its investor conference call?
The investor conference call is scheduled for February 25, 2025.
What innovative technologies does Masimo develop?
Masimo develops several monitoring technologies including Masimo SET® pulse oximetry and various automated solutions for patient care.
How does Masimo's financial performance impact its operations?
Masimo's financial performance reflects its operational efficiency, growth capabilities, and its commitment to enhancing healthcare solutions.
